intensity of each graph was analyzed by considering the reactions between different stages with the different cell line lysate. Although the degree of intensity was totally different between cell lines lysate and serum from I to IV Stages of CRC patients, we were unable to find a unique band specifically relating to one special cell line lysate or specific stage of CRC.
Discussion
It is a long period that researchers follow-up various studies for early detection of CRC by using an affordable, convenient, and noninvasive method. More generally serum biomarkers are one of the useful tools that may offer insight into prognosis, provide diagnostic plan or used for monitoring the treatment response, blood samples are practically easy to obtain and contain antibodies generated against tumor antigens that may serve as a promising source of biomarkers.
Albeit there has been an improvement in current knowledge of CRC molecular pathogenesis in the last two decades, still reliable and robust biomarkers are lacking to allow screening, surveillance, and primary prevention of this disease.
[17] Therefore, diagnosis and treatment of CRC continue to be dependent on descriptive classification and staging systems which are mainly based on morphology and histology.
[17] Utilizing humoral immunity may help us to find biomarkers for detection, prognosis and treatment of CRC patients. In fact, humoral immune response results in the production of aAbs against tumor antigens. CRC patient's sera contain aAbs that react with cancer associated or cancer-specific antigens.
In this study, we found that the immune reactivity patterns of CRC patient's sera of distinct disease stages with two CRC cell lines (SW48 and SW1116) are different from the pattern of normal sera in reaction with the same cell lines. The results confirmed that the most level of aAbs was present in sera from Stage III CRC patients that react with SW48 cell lysate. According to TNM staging system of bowel cancer, Stage III of CRC, has extended outside the colon to one or more nearby lymph nodes but no cancer spread to any other part of the body is observed. Although Suppiah et al., [18] reported that there is no significant difference in aAbs against a human p53 protein in different stages of the CRC patients' sera. However, Kojima et al., [19] described that the production of aAbs against markers such as carcinoembryonic antigen (CEA), p53 and CEA-IgM complexes were different at I-IV Stages of CRC patients and the highest aAbs level was measured in Stage III of disease. Also, Lechpammer et al. suggest that the existence of aAb against p53 in CRC patients' sera is a sign of tumors with more advanced histopathologic stages (Dukes' B, C). [20] One possibility is that in the regional lymph nodes, TAAs or tumor specific antigens stimulate the immune responses. While the immune system response may be induced before the presence of tumor antigens in lymph nodes, our study proved that most humoral immune response occurs in Stage III of CRC disease. Furthermore, the present results illustrated that SW48 cell lysate in reaction with a different stage of CRC patient's sera has higher intensity bands than SW1116 cell lysate. SW48 cell line has higher invasive properties when compared with the SW1116 cell line.
[21] High invasive properties are associated with expression variation of certain molecules like matrix metalloproteinase (MMP2) and MMP9.
[21] Therefore, an increased expression of some proteins (related to SW48 invasiveness) during invasion/ migration process may stimulate an immune response. Sera from Stage III CRC patients contain aAbs that react with tumor cell lines lysate and our results demonstrated that intensity of immune reactivity bands with SW48 cell line was significantly higher than SW1116. This may be because tumor cells migration to lymph node occurs due to the expression of some proteins involved in invasion/migration process. SW48 cell line has such proteins; consequently, it shows the highest intensity in immune reactive bands. In recent years, many studies have been conducted to find aAbs against TAAs. Also numerous aAb markers with good diagnostic efficacy have been determined which can distinguish healthy controls from CRC patients.
[22]
The present study is our first investigation in screening candidate tumor antigens in CRC and additional studies on tumor tissues are required that might identify other antigens that elicit humoral immune responses. Also, through further studies these antigens need to be identified by high-throughput techniques.
Due to the humoral immune response that reacted with infiltrated tumor cells into the lymph node, sera from Stage III CRC patients contained aAbs that demonstrated higher immune reactivity. Moreover, SW48 cell line with high aggressive behavior reacted to CRC patients' sera with greater intensity compared to less aggressive behavior cell line (SW1116).
Conclusion
We have identified the presence of aAbs with high immune reactivity properties in Stage III CRC patients sera that reacted with protein extraction from SW48 cell lines. Therefore, it is required to use high throughput techniques such as two-dimensional electrophoresis and mass spectrometry so that differences in the immunoblotting pattern of CRC patients' sera and cell lines could be identified with more details.
